Aster DM, Minda Industries, RailTel, Bayer Corp shares surge up to 14% intraday post Q4 results – Brokerage sees up to 34% upside

Share

Tweet

Share

Share

Email

Comments

On the back of strong/healthy March quarter results in FY22, shares of Aster DM Healthcare, Minda Industries, RailTel Corporation, Bayer CropScience, and Strides Pharma gained up to 14 per cent on the BSE intraday during Wednesday’s trading session. 

These companies reported their fourth-quarter earnings on Wednesday, wherein the majority of them registered strong revenue growth year-on-year and also improved their margins during the quarter, according to their regulatory filings to the exchanges.

Read More:-Ethos IPO share allotment: Here is how to check status on BSE, KFintech

Aster DM Healthcare jumped most of the above-mentioned stocks, up around 14 per cent to touch a day’s high level of Rs 197 apiece, while Minda Industries and RailTel shares gained around 8.5 per cent each to touch a respective day’s high level of Rs 906.5 and Rs 103 apiece on the BSE intraday. 

Similarly, Bayer Crop shares gained over 7 per cent to touch the day’s high level of Rs 5078.5 per share, and Strides Pharma shares jumped nearly 5 per cent to touch the day’s high of Rs 317.6 per share on the BSE intraday, the latter failed to be in green and fell around 1 per cent intraday. 

Read More:-After relief on edible oil, sugar price rise to be prevented! Government takes big decision

Kotak Institutional Equities in its report being bullish on Aster DM Healthcare suggested to Buy this stock for an upside of 34 per cent or Rs 230 per cent target price. It sees EPS growth of 37 and 17 per cent in FY23 and FY24 respectively. 

For Minda Industries, the brokerage expects the company to report over 15% revenue CAGR over FY2022-25E led by a recovery in the automotive cycle, an increase in kit value led by new product introductions, and premiumization trends and strong order wins across product segments. 

Also Read- 4 Trains Connecting Chhattisgarh With Rajasthan Cancelled; Check List

Kotak Institutional maintained an ADD rating for the stock with a price target of Rs 930 per share (12% upside) as the company’s 4QFY22 results came in better-than-expected.